Birth outcomes after prenatal exposure to antidepressant medication.
about
Pregnancy and delivery while receiving vagus nerve stimulation for the treatment of major depression: a case report.Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalitiesAntidepressant use in pregnancy: a critical review focused on risks and controversiesCognitive impairments from developmental exposure to serotonergic drugs: citalopram and MDMAPrenatal antidepressant exposure: clinical and preclinical findings.Fetal effects of psychoactive drugsClinical issues in perinatal mental health: new developments in the detection and treatment of perinatal mood and anxiety disorders.Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?Treatment of nonpsychotic major depression during pregnancy: patient safety and challengesSafety of newer antidepressants in pregnancy.Paroxetine and neonatal withdrawal syndrome.The safety of antidepressant drugs during pregnancy.Taking antidepressants during late pregnancy. How should we advise women?Depression during pregnancyTreatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline.Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetusSelective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?Do the Levels of Maternal Plasma Trace Elements Affect Fetal Nuchal Translucency Thickness?Perinatal citalopram exposure selectively increases locus ceruleus circuit function in male rats.Neonatal serotonin syndrome.Drug use and breastfeeding.Maternal depression and medication exposure during pregnancy: comparison of maternal retrospective recall to prospective documentationIncrease in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.Perinatal depression: treatment options and dilemmas.The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspringSerotonin contributes to high pulmonary vascular tone in a sheep model of persistent pulmonary hypertension of the newbornThe safety of pharmacological therapies for gastrointestinal conditions encountered during pregnancy.Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational studyThe use of central nervous system active drugs during pregnancy.Prenatal depression and selective serotonin reuptake inhibitors.Antidepressant use in pregnancy.Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.The Effectiveness of Mindfulness-Based Interventions on Maternal Perinatal Mental Health Outcomes: a Systematic Review.Managing depression during pregnancy.The effects of maternal depression and use of antidepressants during pregnancy on risk of a child small for gestational age.Breastfeeding among women exposed to antidepressants during pregnancy.Chronic maternal fluoxetine infusion in pregnant sheep: effects on the maternal and fetal hypothalamic-pituitary-adrenal axes.Antidepressant drug use in pregnancy.Maternal fluoxetine infusion does not alter fetal endocrine and biophysical circadian rhythms in pregnant sheep.
P2860
Q24814119-188A8FC5-72DD-42ED-9E43-98FC4203E2CFQ27300825-0C34FD6C-8592-47AC-B0BE-CB95F4BA777FQ28281407-ADA69F10-E8B7-4EED-A479-2355B7F0E268Q30401455-E27B9363-7545-499E-8BFA-39009C6E8CBDQ30415540-817D3022-BD7E-4B0A-BFAE-CF3DB325A361Q30479705-024D0588-ACEF-4034-A6DF-88257B4A11D2Q30787634-95166D43-8662-4528-8D33-0B1E2830FE3EQ33940520-FBC6717A-1086-41F6-A3FE-322CE89DD422Q34237681-8076039D-4C51-4B47-8231-2861AB810DB2Q34611697-87C2D646-819C-4015-987A-0C31F5811332Q34618623-4F4DD659-1FA6-46E9-8E1F-D3DB039BD8DAQ34661348-E90E2523-7355-472B-8EC6-ADBAE578B8FBQ34682589-FB3E16A8-0899-493A-AEA1-03E825B9752DQ34682688-9F191CF2-932A-4AD8-BFB6-780033457D61Q35575008-144FF743-6DA4-4826-9A28-976A38A0638DQ35601447-66A59236-9405-466F-AE20-6B4A3656B9F1Q35608913-C3E64F51-526C-4867-AACA-692B8D85C574Q35772910-5E1CD098-EF71-420D-948B-C37FE3ABFF89Q35853507-C74F4545-A08D-453C-826E-8E3851FEDC59Q36144223-3E1CCF72-C46C-4BD1-AC77-2409DCB22297Q36191050-A4B82923-729D-4730-96AA-80A2CF0C302AQ36467145-956E77D2-A78C-4056-A861-011D99494414Q36536492-AB112FBA-5ACE-432D-922B-982FD7B7ABB5Q36706789-9FC8161F-0408-4148-9DC0-CDD33BCEBBD9Q36737979-E4C4789A-58CA-4D06-A6C2-01167522F3B7Q36860205-3F0209AF-75B0-4BCA-BFDB-A5C18709FADFQ36923860-BB5D1536-3EA6-474A-8B1A-44D6911A1927Q36945003-E3A3CBB4-4130-4B34-86DC-70D9E356EF2FQ37142457-96E78E77-DF76-4EEB-BA0E-1BD1500B0F63Q37280003-F5E57F0D-EFFC-4D5D-942B-071282285881Q37726017-C27F73BB-5993-4C29-B11E-9EF0E7E282E0Q37872295-95C75539-D892-4C23-8EA3-2C0CBC02DDA1Q37943435-BF4774B6-B299-4B5C-BEC2-DE0787D279C9Q40987166-8BA1F756-F5E1-4F6E-8D99-8091670F7131Q43451478-6229CFB5-6E14-41CA-AA8B-1B0B0B4ABECFQ43616101-A06FD12D-14F6-4286-8829-9EEB0B387AC6Q44649267-2DCB9AFD-3762-46CE-B1FF-F944F6A2C995Q44885208-FC865069-7320-4407-8531-E33C5298B91AQ46567640-754E47CB-02EC-4B3A-A464-E0AEFBC813AAQ46567654-1BDE8257-BDE2-4639-B6C1-D97ADE7E0308
P2860
Birth outcomes after prenatal exposure to antidepressant medication.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Birth outcomes after prenatal exposure to antidepressant medication.
@ast
Birth outcomes after prenatal exposure to antidepressant medication.
@en
type
label
Birth outcomes after prenatal exposure to antidepressant medication.
@ast
Birth outcomes after prenatal exposure to antidepressant medication.
@en
prefLabel
Birth outcomes after prenatal exposure to antidepressant medication.
@ast
Birth outcomes after prenatal exposure to antidepressant medication.
@en
P2093
P356
P1476
Birth outcomes after prenatal exposure to antidepressant medication.
@en
P2093
Desiree Haynes
Lori Altshuler
Lynne M Smith
Victoria Hendrick
P304
P356
10.1067/MOB.2003.172
P407
P577
2003-03-01T00:00:00Z